{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T14:05:39Z","timestamp":1750687539836,"version":"3.40.5"},"reference-count":34,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T00:00:00Z","timestamp":1572998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To identify factors associated with the development of adverse drug reactions (ADR) in ribavirin therapeutic regimens.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A multicenter, prospective study was conducted in three public health hospitals in Rio de Janeiro between November 2015 and March 2018. Inclusion criteria were defined by patient follow\u2010up at pharmaceutical consultation at the time of drug dispensing as those who used sofosbuvir in combination with simeprevir, daclatasvir, and\/or ribavirin. All patients were invited to participate in the study during the first interview. Adverse drug reactions were reported according to the treatment regimen and frequency of occurrence. Statistical analysis was used to compare adverse reactions between treatments and their associated factors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 405 patients were included in the study (mean age 59.6 \u00b1 9.6 years); 61.0% were female, 88.1% were infected with genotype 1, and 65.4% were cirrhotic. The most prescribed treatment was the combination of sofosbuvir, daclatasvir, and ribavirin (55.3%). The majority of patients reported at least one ADR during treatment (83.2%), of which fatigue, anemia, and headache were the most common. Being female (OR = 1.86, [1.08\u20103.20]) and use of ribavirin (OR: 2.39; 95% CI [1.38\u20104.13]) were predictors for the development of ADR, which was also associated with development of anemia (OR: 10.28; 95% CI: [5.78\u201018.30]). Treatment efficacy was 98.1%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Direct\u2010acting antiviral has been shown to be safe and effective. Therefore, use of ribavirin is questionable due to associated adverse reactions and similar efficacy to other treatments.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.4904","type":"journal-article","created":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T11:49:28Z","timestamp":1573040968000},"page":"1601-1608","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Predictors of adverse drug reactions associated with ribavirin in direct\u2010acting antiviral therapies for chronic hepatitis C"],"prefix":"10.1002","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0904-2787","authenticated-orcid":false,"given":"Camille Nigri","family":"Cursino","sequence":"first","affiliation":[{"name":"Mestrado Profissional em Administra\u00e7\u00e3o e Gest\u00e3o da Assist\u00eancia Farmac\u00eautica, Faculdade de Farm\u00e1cia Universidade Federal Fluminense  Rio de Janeiro Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9597-665X","authenticated-orcid":false,"given":"Priscilla Garcia de Oliveira","family":"Monteiro","sequence":"additional","affiliation":[{"name":"Mestrado Profissional em Administra\u00e7\u00e3o e Gest\u00e3o da Assist\u00eancia Farmac\u00eautica, Faculdade de Farm\u00e1cia Universidade Federal Fluminense  Rio de Janeiro Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9823-2034","authenticated-orcid":false,"given":"Gabriel da Silva","family":"Duarte","sequence":"additional","affiliation":[{"name":"Mestrado Profissional em Administra\u00e7\u00e3o e Gest\u00e3o da Assist\u00eancia Farmac\u00eautica, Faculdade de Farm\u00e1cia Universidade Federal Fluminense  Rio de Janeiro Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6803-7016","authenticated-orcid":false,"given":"Tassita Bezz Quintanilha","family":"Vieira","sequence":"additional","affiliation":[{"name":"Faculdade de Farm\u00e1cia Universidade Federal Fluminense  Rio de Janeiro Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8576-8048","authenticated-orcid":false,"given":"Ver\u00f4nica de Carvalho","family":"Crisante","sequence":"additional","affiliation":[{"name":"Faculdade de Farm\u00e1cia Universidade Federal Fluminense  Rio de Janeiro Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2919-856X","authenticated-orcid":false,"given":"Fab\u00edola","family":"Giordani","sequence":"additional","affiliation":[{"name":"Faculdade de Medicina Universidade Federal Fluminense  Rio de Janeiro Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4501-1857","authenticated-orcid":false,"given":"Anal\u00facia Rampazzo","family":"Xavier","sequence":"additional","affiliation":[{"name":"Faculdade de Farm\u00e1cia Universidade Federal Fluminense  Rio de Janeiro Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0158-7432","authenticated-orcid":false,"given":"Renan Moritz Varnier Rodrigues","family":"de Almeida","sequence":"additional","affiliation":[{"name":"PEB\/Instituto Alberto Luiz Coimbra de P\u00f3s\u2010gradua\u00e7\u00e3o e Pesquisa de Engenharia, Universidade Federal do Rio de Janeiro  Rio de Janeiro Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2026-1510","authenticated-orcid":false,"given":"Sabrina","family":"Calil\u2010Elias","sequence":"additional","affiliation":[{"name":"Mestrado Profissional em Administra\u00e7\u00e3o e Gest\u00e3o da Assist\u00eancia Farmac\u00eautica, Faculdade de Farm\u00e1cia Universidade Federal Fluminense  Rio de Janeiro Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,11,6]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0004-28032015000100001"},{"key":"e_1_2_9_3_1","unstructured":"World Health Organization.Global Hepatitis Report.2017."},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.29033"},{"key":"e_1_2_9_5_1","article-title":"Approaches, Progress, and Challenges to Hepatitis C Vaccine Development","author":"Bailey JR","year":"2018","journal-title":"Gastroenterology"},{"issue":"60","key":"e_1_2_9_6_1","first-page":"1","article-title":"Prevalence and risk factors of Hepatitis C virus infection in Brazil, 2005 through 2009: a cross\u2010sectional study","volume":"13","author":"Pereira LM","year":"2013","journal-title":"BMC Infectious Disease."},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62401-6"},{"volume-title":"Brasil. Minist\u00e9rio da Sa\u00fade. Secretaria de Vigil\u00e2ncia em Sa\u00fade","key":"e_1_2_9_8_1","first-page":"2018"},{"key":"e_1_2_9_9_1","unstructured":"Brasil. Departamento de DST AIDS e Hepatites Virais. Hepatite C. In: Vigil\u00e2ncia Preven\u00e7\u00e3o e Controle dos IST do HIV\/Aids e das Hepatites Virais [internet].2016Apr 23. Available from:http:\/\/www.aids.gov.br\/pt\u2010br\/publico\u2010geral\/o\u2010que\u2010sao\u2010hepatites\/hepatite\u2010c."},{"issue":"2","key":"e_1_2_9_10_1","first-page":"202","article-title":"New drugs: simeprevir, sofosbuvir, and dolutegravir sodium","volume":"54","author":"Hussar D","year":"2014","journal-title":"Journal of the American Pharmacists"},{"key":"e_1_2_9_11_1","unstructured":"Brasil.Minist\u00e9rio da Sa\u00fade. Secretaria de Vigil\u00e2ncia em Sa\u00fade. Departamento de DST AIDS e Hepatites Virais. Protocolos Cl\u00ednicos e Diretrizes Terap\u00eauticas para Hepatite C Cr\u00f4nica e Coinfec\u00e7\u00f5es.Bras\u00edlia:2016b."},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13514"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-017-0552-1"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjid.2018.04.003"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/1751-2980.12313"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.13743"},{"volume-title":"Minist\u00e9rio da Sa\u00fade. Secretaria de Vigil\u00e2ncia em Sa\u00fade. Departamento de DST, AIDS e Hepatites Virais. Suplemento 1. Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas para Hepatite Viral C e Coinfec\u00e7\u00f5es","year":"2013","author":"Brasil","key":"e_1_2_9_17_1"},{"key":"e_1_2_9_18_1","unstructured":"PNCQ \u2013 Programa Nacional de Controle de Qualidade.Informa\u00e7\u00f5es t\u00e9cnicas \u2013 Valores Normais de Hemograma.2016Oct 25. Available from:www.pncq.org.br\/uploads\/2012\/06\/valores_normais_hemograma.pdf."},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781118548387"},{"volume-title":"Hepatite por VHC \u2010 Aspectos Virol\u00f3gicos e suas Implica\u00e7\u00f5es Pr\u00e1ticas","year":"2008","author":"Barone AA","key":"e_1_2_9_20_1"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0037-86822001000100011"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0104-42302011000100024"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000001192"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2006.01354.x"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181e36420"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200102060-00001"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1586\/ecp.11.29"},{"issue":"24955","key":"e_1_2_9_28_1","first-page":"1","article-title":"Systematic Analysis of Adverse Event Reports for Sex Differences in Adverse Drug Events","volume":"6","author":"Yu Y","year":"2016","journal-title":"Scientific Reports."},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.5604\/01.3001.0010.2717"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1590\/1414-431x20165300"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/lt.24324"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28473"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2016.07.001"},{"volume-title":"Minist\u00e9rio da Sa\u00fade. Secretaria de Vigil\u00e2ncia em Sa\u00fade. Departamento de DST, AIDS e Hepatites Virais","year":"2017","author":"Brasil","key":"e_1_2_9_34_1"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2014.01.005"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.4904","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.4904","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pds.4904","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.4904","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T14:44:11Z","timestamp":1694184251000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.4904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,6]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["10.1002\/pds.4904"],"URL":"https:\/\/doi.org\/10.1002\/pds.4904","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"type":"print","value":"1053-8569"},{"type":"electronic","value":"1099-1557"}],"subject":[],"published":{"date-parts":[[2019,11,6]]},"assertion":[{"value":"2019-05-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}